n-Lorem Foundation Partners with Cytiva to Bring Individualized ASO Medicines to Patients with Nano-rare Diseases
Cytiva donates equipment totaling $415,000 [...]
n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare Diseases
Argonaut to support n-Lorem’s expanding [...]
Antisense oligonucleotide as a therapeutic approach in amyotrophic lateral sclerosis
Korobeynikov, V.A., Lyashchenko, A.K., Blanco-Redondo, B., Jafar-Nejad, P. Shneider, N.A.
n-Lorem Foundation Announces New Publication in Trends in Molecular Medicine
Publication highlights the [...]
John Maraganore Joins the n-Lorem Foundation Team as Chair of Its Advisory Council
John Maraganore pledges [...]
IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Download PDF
